Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results ...

Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...

Dysbiosis is the condition of having imbalances in the microbial communities either in or on the body. Dysbiosis is associated with many diseases, such as inflammatory bowel disease and chronic ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

The product has been replaced with a new NDC number. Pirfenidone: Genetech has discontinued the 267-milligram presentation of pirfenidone capsule used for pulmonary/allergy treatments ...

On the other hand, rise in number of pipeline drugs and untapped potential in developing countries present new opportunities in the coming years. Based on drug type, the pirfenidone segment accounted ...

Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue ...

PDE has a strong anti-fibrosis effect but needs more in-depth research. (7) Pirfenidone has broad-spectrum anti-fibrosis effects and is the first drug to demonstrate some efficacy for IPF, which was ...

Kohen's team explored pirfenidone (PFD) for its antifibrotic activity, aiming to reduce scarring around GDDs without the ...